



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

# Transfusion and Apheresis Science

journal homepage: [www.elsevier.com/locate/transci](http://www.elsevier.com/locate/transci)

## Editorial

**Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount**



In this What's Happening commentary, as a follow up of *transci* 60.1 on the "New Generation of Vaccines and Convalescent Plasma Therapy for Management of CoV-2". I am opting to remain on the same hot topic which is of current interest to all at the international level.

Currently coronavirus virus has challenged human ingenuity, and the infection-associated death is reaching now reaching 3 million and still rising with the appearance of newer fast transmissible Brazilian variants on the scene. This event amplified even further by the colder months, traveling season and the participation in various social events as well as dropping our guard too early. However, with the on-going mass distribution of multiple vaccines and the targeted use of newly proven pharmaceutical bioproducts and advanced technologies to mitigate infections and prevent deaths there is some hope we will survive this

deadly infection. With these considerations in mind, I have invited two colleagues from Norway and the USA to provide a concise review, on their take of a working title: "The story of a different year, with enormous challenges imposed by CoV-2 variants and how we have responded on the way back to normality. I am most grateful for their timely delivery and for helping me, as a team, in this New Year's joint venture.

Jerard Seghatchian  
*International Consultancy in Innovative Manufacturing and Quality/Safety  
of Blood-Derived Bioproducts, London, England, UK*  
E-mail address: [jsegghatchian@btopenworld.com](mailto:jsegghatchian@btopenworld.com).

<https://doi.org/10.1016/j.transci.2021.103091>

Available online 18 February 2021  
1473-0502/© 2021 Published by Elsevier Ltd.